Lactate is a possible mediator of the glucose effect on platelet inhibition

References

• Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010;7:251–259
   PubMed Web of Science ®Google Scholar
• Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res 2012;129:116–126
   PubMed Web of Science ®Google Scholar
• Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 1992;68:577–582
   PubMed Web of Science ®Google Scholar
• Watala C, Golański J, Boncler MA, Pietrucha T, Gwoździński K. Membrane lipid fluidity of blood platelets: A common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 1998;9:315–327
   PubMed Web of Science ®Google Scholar
• Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short-term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001;44:188–195
   PubMed Web of Science ®Google Scholar
• Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003;92:1362–1365
   PubMed Web of Science ®Google Scholar
• Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N. High glucose levels enhance platelet activation: Involvement of multiple mechanisms. Br J Haematol 2006;133:315–322
   PubMed Web of Science ®Google Scholar
• Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 2011;121:4462–4476
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153–1161
   PubMed Web of Science ®Google Scholar
• Massucco P, Mattiello L, Russo I, Traversa M, Doronzo G, Anfossi G, Trovati M. High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism. Thromb Haemost 2005;93:517–526
   PubMedGoogle Scholar
• De La Cruz JP, Arrebola MM, Villalobos MA, Pinacho A, Guerrero A, González-Correa JA, Sánchez de la Cuesta F. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur J Pharmacol 2004;484:19–27
   PubMed Web of Science ®Google Scholar
• Le Guyader A, Pacheco G, Seaver N, Davis-Gorman G, Copeland J, McDonagh PF. Inhibition of platelet GPIIb-IIIa and P-selectin expression by aspirin is impaired by stress hyperglycemia. J Diabetes Complications 2009;23:65–70
   PubMed Web of Science ®Google Scholar
• Kobzar G, Mardla V, Samel N. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors. Platelets 2011;22:338–344
   PubMed Web of Science ®Google Scholar
• Chen L, Salafranca MN, Mehta JL. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am J Physiol 1997;273:H1854–H1859
   PubMed Web of Science ®Google Scholar
• O'Kane PD, Queen LR, Ji Y, Reebye V, Stratton P, Jackson G, Ferro A. Aspirin modifies nitric oxide synthase activity in platelets: Effects of acute versus chronic aspirin treatment. Cardiovasc Res 2003;59:152–159
   PubMed Web of Science ®Google Scholar
• O'Kane P, Xie L, Liu Z, Queen L, Jackson G, Ji Y, Ferro A. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 2009;83:123–130
   PubMed Web of Science ®Google Scholar
• Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003;14:421–427
   PubMed Web of Science ®Google Scholar
• Ferreira IA, Mocking AI, Urbanus RT, Varlack S, Wnuk M, Akkerman JW. Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B. J Biol Chem 2005;280:32625–32633
   PubMed Web of Science ®Google Scholar
• Naito E, Kuroda Y, Toshima K, Takeda E, Saijo T, Kobashi H, Yokota I, Ito M. Effect of sodium dichloroacetate on human pyruvate metabolism. Brain Dev 1989;11:195–197
   Google Scholar
• Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr. Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996;94:2434–2440
   PubMed Web of Science ®Google Scholar
• Freedman JE, Li L, Sauter R, Keaney JF Jr. Alpha-tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release. FASEB J 2000;14:2377–2379
   PubMed Web of Science ®Google Scholar
• Li D, Saldeen T, Romeo F, Mehta JL. Different isoforms of tocopherols enhance nitric oxide synthase phosphorylation and inhibit human platelet aggregation and peroxidation: Implications in therapy with vitamin E. J Cardiovasc Pharmacol Ther 2001;6:155–161
   PubMedGoogle Scholar
• Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Balbo A, Trovati M. Adenosine increases human platelet levels of cGMP through nitric oxide: Possible role in its antiaggregating effect. Thromb Res 2002;105:71–78
   PubMed Web of Science ®Google Scholar
• Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res 2004;114:265–273
   Google Scholar
• Anfossi G, Russo I, Massucco P, Mattiello L, Perna P, Tassone F, Trovati M. l-arginine modulates aggregation and intracellular cyclic 3,5-guanosine monophosphate levels in human platelets: Direct effect and interplay with antioxidative thiol agent. Thromb Res 1999;94:307–316
   Google Scholar
• Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205–229
   PubMed Web of Science ®Google Scholar
• Radomski MW, Palmer RM, Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193–5197
   PubMed Web of Science ®Google Scholar
• Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol 1990;101:325–328
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Balbo A, Trovati M. Adenosine increases human platelet levels of cGMP through nitric oxide: Possible role in its antiaggregating effect. Thromb Res 2002;105:71–78
   PubMed Web of Science ®Google Scholar
• Li D, Saldeen T, Romeo F, Mehta JL. Different isoforms of tocopherols enhance nitric oxide synthase phosphorylation and inhibit human platelet aggregation and peroxidation: Implications in therapy with vitamin E. J Cardiovasc Pharmacol Ther 2001;6:155–161
   PubMedGoogle Scholar
• Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res 2007;101:654–662
   PubMed Web of Science ®Google Scholar
• Priora R, Margaritis A, Frosali S, Coppo L, Summa D, Di Giuseppe D, Aldinucci C, Pessina G, Di Stefano A, Di Simplicio P. In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways. Pharmacol Res 2011;64:289–297
   Google Scholar
• Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 2001;41:203–236
   PubMed Web of Science ®Google Scholar
• Boulos C, Jiang H, Balazy M. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues. J Pharmacol Exp Ther 2000;293:222–229
   PubMed Web of Science ®Google Scholar